SynAct Pharma shareholders propose Marina Bozilenko as new board member
SynAct Pharma AB ("SynAct") today announced that shareholders representing more than 20 per cent of the shares and votes in the company propose Marina Bozilenko to be elected as new board member of SynAct Pharma at the next annual general meeting set for May 21, 2021.
Marina Bozilenko has more than 30 years of experience in investment banking and the healthcare industry, including raising more than $30 billion in capital and executing numerous M&A transactions.
Ms. Bozilenko currently serves as Strategic Advisor to William Blair & Company, a firm she joined in 2010 as Head of Biotech & Pharma and Managing Director. Prior to that, she worked at Bear, Stearns & Co. Inc. as a senior managing director in the healthcare group, at Bank of America Securities as a managing director and head of biotechnology, and at Vector Securities International, where she was a partner. She also currently serves as Director of the biotech company AcelRx Pharmaceuticals and on the Advisory Board of Arctic Aurora Life Sciences, a Swedish healthcare-focused investment fund.
She received her B.A. in molecular biology and M.A. in economic history from the University of Chicago.
“Marina is an amazing talent with superb experience in both the pharmaceutical and banking sectors, a wonderful addition for SynAct,” said Torbjörn Bjerke, Chairman of SynAct Pharma. “Marina will be a key asset to the company as we push forward with our growth plans.”
For more information, please refer to the notice to the annual general meeting, which will be published as a separate press release.
The information was submitted, through the agency of the contact person below, for publication on April 19, 2021.
For further information about SynAct Pharma AB, please contact:
Jeppe Øvlesen Thomas Jonassen
CEO, SynAct Pharma AB CSO, SynAct Pharma AB
Phone: +45 28 44 75 67 Phone: +45 40 15 66 69
Mail: email@example.com Mail: firstname.lastname@example.org
About SynAct Pharma AB
SynAct Pharma AB conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: www.synactpharma.com.